Loading...
Thumbnail Image
Publication

Comparative analysis of deep learning and radiomic signatures for overall survival prediction in recurrent high-grade glioma treated with immunotherapy

Wan, Qi
Lindsay, Clifford
Zhang, Chenxi
Kim, Jisoo
Chen, Xin
Li, Jing
Huang, Raymond Y
Reardon, David A
Young, Geoffrey S
Qin, Lei
Embargo Expiration Date
Abstract

Background: Radiomic analysis of quantitative features extracted from segmented medical images can be used for predictive modeling of prognosis in brain tumor patients. Manual segmentation of the tumor components is time-consuming and poses significant reproducibility issues. We compare the prediction of overall survival (OS) in recurrent high-grade glioma(HGG) patients undergoing immunotherapy, using deep learning (DL) classification networks along with radiomic signatures derived from manual and convolutional neural networks (CNN) automated segmentation.

Materials and methods: We retrospectively retrieved 154 cases of recurrent HGG from multiple centers. Tumor segmentation was performed by expert radiologists and a convolutional neural network (CNN). From the segmented tumors, 2553 radiomic features were extracted for each case. A robust feature subset was selected using intraclass correlation coefficient analysis between manual and automated segmentations. The data was divided into a 9:1 ratio and validated through ten-fold cross-validation and tested on a rotating test set. Features selection was done by the Kruskal-Wallis test. The Radiomics-based OS predictions, generated using Support Vector Machine (SVM), were compared between the two segmentation approaches and against OS prediction by the CNN model adapted for classification. Model efficacy was evaluated using the area under the receiver operating characteristic curve (AUC).

Results: The clinical model AUC for OS prediction was 0.640 ± 0.013 (mean ± 95% confidence interval) in the training set and 0.610 ± 0.131 in the test set. The radiomics prediction of OS based on manual segmentation outperformed automatic segmentation (AUC of 0.662 ± 0.122 vs. 0.471 ± 0.086, respectively) in the test set. Robust features improved the performance of manual segmentation to AUC of 0.700 ± 0.102, of automated segmentation to 0.554 ± 0.085. The CNN prognosis model demonstrated promising results, with an average AUC of 0.755 ± 0.071 for training sets and 0.700 ± 0.101 for the test set.

Conclusion: Manual segmentation-derived radiomic features outperformed automated segmentation-derived features for predicting OS in recurrent high-grade glioma patients undergoing immunotherapy. The end-to-end CNN prognosis model performed similarly to radiomics modeling using manual-segmentation-derived features without the need for segmentation. The potential time-saving must be weighed against the lower interpretability of end-to-end black box modeling.

Source

Wan Q, Lindsay C, Zhang C, Kim J, Chen X, Li J, Huang RY, Reardon DA, Young GS, Qin L. Comparative analysis of deep learning and radiomic signatures for overall survival prediction in recurrent high-grade glioma treated with immunotherapy. Cancer Imaging. 2025 Jan 21;25(1):5. doi: 10.1186/s40644-024-00818-0. PMID: 39838503; PMCID: PMC11752626.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1186/s40644-024-00818-0
PubMed ID
39838503
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
© The Author(s) 2024. Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Attribution 4.0 International